| Theme | Preventive Medicine of Gastrointestinal Cancer | |
|---|---|---|
| Title | Prevention of Biliary Tract Carcinogenesis in Pancreaticobiliary Maljunction | |
| Publish Date | 2006/06 | |
| Author | Akihiko Tsuchida | Third Department of Surgery, Tokyo Medical University |
| Author | Itsuro Nagae | Third Department of Surgery, Tokyo Medical University |
| Author | Hitoshi Saito | Third Department of Surgery, Tokyo Medical University |
| Author | Takahisa Ikeda | Third Department of Surgery, Tokyo Medical University |
| Author | Yoshihide Tanabe | Third Department of Surgery, Tokyo Medical University |
| Author | Soshi Takahashi | Third Department of Surgery, Tokyo Medical University |
| Author | Tatsuya Aoki | Third Department of Surgery, Tokyo Medical University |
| Author | Takao Itoi | Fourth Department of Internal Medicine, Tokyo Medical University |
| [ Summary ] | Pancreaticobiliary maljunction (PBM) is a congenital anomaly. Due to the reciprocal reflux of pancreatic juice and bile, carcinogenic substances including activated pancreatic enzymes, secondary bile acid etc. are produced. Since the biliary tract mucosa may be damaged over long period, several epithelial changes including hyperplasia, metaplasia or dysplasia may occur, resulting in high carcinogenesis rates. The primary treatment for PBM without cancer is preventive cholecystectomy and resection of the extrahepatic bile duct. However, cholecystectomy alone is performed for cases without dilatation of the extrahepatic bile duct in about fifty percent of hospitals. To evaluate the possibility of chemoprevention for PBM, we performed animal experiments using hamster PBM models and confirmed the anticancer effects of a COX-2 selective inhibitor and vitamin K2. | |